Clene (CLNN) to Meet with FDA to Discuss ALS Biomarker and Clinical Data
Clene (CLNN) and its subsidiary Clene Nanomedicine Inc. are scheduled to meet with FDA officials to discuss the CNM-Au8 biomarker and related clinical data for ALS. This meeting holds significance for the understanding and potential treatment of ALS.
This news matters because it highlights Clene's efforts to address neurodegenerative diseases like ALS. The outcome of the meeting could impact the understanding and treatment of ALS, potentially benefiting patients with the condition.
